Results
|
21.
|
|
|
22.
|
|
|
23.
|
|
|
24.
|
|
|
25.
|
|
|
26.
|
|
|
27.
|
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. [electronic resource] by
- Choueiri, T K
- Motzer, R J
- Rini, B I
- Haanen, J
- Campbell, M T
- Venugopal, B
- Kollmannsberger, C
- Gravis-Mescam, G
- Uemura, M
- Lee, J L
- Grimm, M-O
- Gurney, H
- Schmidinger, M
- Larkin, J
- Atkins, M B
- Pal, S K
- Wang, J
- Mariani, M
- Krishnaswami, S
- Cislo, P
- Chudnovsky, A
- Fowst, C
- Huang, B
- di Pietro, A
- Albiges, L
Producer: 20210106
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 31
Availability: No items available.
|
|
28.
|
|
|
29.
|
|
|
30.
|
|
|
31.
|
|
|
32.
|
|
|
33.
|
|
|
34.
|
Kidney cancer, version 3.2015. [electronic resource] by
- Motzer, Robert J
- Jonasch, Eric
- Agarwal, Neeraj
- Beard, Clair
- Bhayani, Sam
- Bolger, Graeme B
- Chang, Sam S
- Choueiri, Toni K
- Costello, Brian A
- Derweesh, Ithaar H
- Gupta, Shilpa
- Hancock, Steven L
- Kim, Jenny J
- Kuzel, Timothy M
- Lam, Elaine T
- Lau, Clayton
- Levine, Ellis G
- Lin, Daniel W
- Michaelson, M Dror
- Olencki, Thomas
- Pili, Roberto
- Plimack, Elizabeth R
- Rampersaud, Edward N
- Redman, Bruce G
- Ryan, Charles J
- Sheinfeld, Joel
- Shuch, Brian
- Sircar, Kanishka
- Somer, Brad
- Wilder, Richard B
- Dwyer, Mary
- Kumar, Rashmi
Producer: 20151109
In:
Journal of the National Comprehensive Cancer Network : JNCCN vol. 13
Availability: No items available.
|
|
35.
|
|
|
36.
|
|
|
37.
|
|
|
38.
|
|
|
39.
|
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. [electronic resource] by
- Lin, Zhong-Zhe
- Chen, Bang-Bin
- Hung, Yi-Ping
- Huang, Po-Hsiang
- Shen, Ying-Chun
- Shao, Yu-Yun
- Hsu, Chih-Hung
- Cheng, Ann-Lii
- Lee, Rheun-Chuan
- Chao, Yee
- Hsu, Chiun
Producer: 20210618
In:
The oncologist vol. 25
Availability: No items available.
|
|
40.
|
|